Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genmont Biotech Inc. (3164:TWSE), powered by AI.
Genmont Biotech Inc. is currently trading at $16.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Genmont Biotech Inc. on Alpha Lenz.
View Genmont Biotech Inc.'s valuation metrics on Alpha Lenz.
“Genmont Biotech Inc.'s ROE is 4.3%. Explore profitability and growth together.”
Ask for details →Genmont Biotech Inc. is a biotechnology company focused on developing, producing, and distributing probiotic products aimed at promoting health and wellness. Its primary function is to leverage cutting-edge research and technology in the field of microbiology to create effective probiotic solutions. The company’s offerings cater to a diverse range of applications, from dietary supplements to functional foods, targeting both individual consumers and various industries, including nutraceuticals and pharmaceuticals. Genmont Biotech Inc. plays a pivotal role in the global wellness market by continually advancing the understanding of probiotics' benefits. Established as a leader in its field, the company is recognized for its commitment to quality and innovation, often collaborating with academic institutions for research and development. As health and wellness trends gain momentum worldwide, Genmont Biotech Inc. positions itself at the forefront of contributing to the evolving landscape of consumer health products.
“Genmont Biotech Inc.'s ROE is 4.3%. Explore profitability and growth together.”
Ask for details →Genmont Biotech Inc. (ticker: 3164) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 16.4 with a P/E ratio of -x and P/B of -x.
ROE is 4.26% and operating margin is 14.57%. Annual revenue is $401M.